Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
Kurahara H, Shinchi H, Ohtsuka T, Miyasaka Y, Matsunaga T, Noshiro H, Adachi T, Eguchi S, Imamura N, Nanashima A, Sakamoto K, Nagano H, Ohta M, Inomata M, Chikamoto A, Baba H, Watanabe Y, Nishihara K, Yasunaga M, Okuda K, Natsugoe S, Nakamura M.
Kurahara H, et al. Among authors: yasunaga m.
Langenbecks Arch Surg. 2019 Mar;404(2):167-174. doi: 10.1007/s00423-019-01754-5. Epub 2019 Jan 16.
Langenbecks Arch Surg. 2019.
PMID: 30649607